Journal of Clinical Lipidology
Volume 4, Issue 4 , Pages 259-264 , July 2010

Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein?

  • Lawrence Baruch, MD

      Affiliations

    • James J. Peters VA Medical Center (Medical Service), 130 West Kingsbridge Road, Bronx, NY 10468
    • Mt. Sinai School of Medicine, New York, NY
    • Corresponding Author InformationCorresponding author:
    • ,
  • Sanjay Agarwal, MD

      Affiliations

    • Valley Hospital, Ridgewood, NJ
    • ,
  • Bhanu Gupta, MD

      Affiliations

    • Mayo Clinic, Rochester, MN
    • ,
  • Ann Haynos, BA

      Affiliations

    • University of Nevada, Reno, NV
    • ,
  • Swapna Johnson, MD

      Affiliations

    • James J. Peters VA Medical Center (Medical Service), 130 West Kingsbridge Road, Bronx, NY 10468
    • ,
  • Katelyn Kelly-Johnson, BS

      Affiliations

    • James J. Peters VA Medical Center (Medical Service), 130 West Kingsbridge Road, Bronx, NY 10468
    • ,
  • Calvin Eng, MD

      Affiliations

    • James J. Peters VA Medical Center (Medical Service), 130 West Kingsbridge Road, Bronx, NY 10468
    • Mt. Sinai School of Medicine, New York, NY

Received 10 March 2010 ,Accepted 31 May 2010.

References 

  1. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486–2497
  2. McPherson J, Frohlich G, Fodor J. Genest. Canadian Cardiovascular Society position statement – recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22:913–927
  3. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  4. Heart Protection Study Collaborative Group. PMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  5. Foley KA, Simpson RJ, Crouse JR, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in subjects at high risk of atherogenic events. Am J Cardiol. 2003;92:79–81
  6. Kastelein JJ, van der Steeg WA, Holme I, et al. TNT Study Group; IDEAL Study Group Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–3009
  7. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–333
  8. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non–high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–3383
  9. Cui Y, Blumenthal RS, Flaws JA, et al. Non–high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–1419
  10. Arsenault BJ, Rana JS, Stroes ESG, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non–high density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2010;55:35–41
  11. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non–high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316–322
  12. Blaha MJ, Roger S, Blumenthal RS, Eliot A, Brinton EA, Jacobson TA on behalf of the National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non–HDL cholesterol reporting in lipid management. J Clin Lipid. 2008;4:267–273
  13. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–1524
  14. Contois JH, McConnell JP, Sethi AA, et al. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55:407–419

PII: S1933-2874(10)00225-4

doi: 10.1016/j.jacl.2010.05.003

Journal of Clinical Lipidology
Volume 4, Issue 4 , Pages 259-264 , July 2010

Article Tools

* Image Usage & Resolution